Celerion has conducted approx. 50 clinical studies for tobacco-product manufactures in the past 15 years, in addition to having over 15 years of experience recruiting smokers for the evaluation of Nicotine Replacement Therapy (NRT) products.
Our two purpose built-facilities, located in Lincoln, Nebraska, and Belfast, Northern Ireland UK, are equipped with 278 beds to accommodate the need for indoor smoking of conventional cigarette comparators necessary to fulfill FDA submission requirements. As indoor smoking laws continue to tighten, statutory laws allow Celerion to offer these services while clinical providers in other locations may not be permitted to do so.
Tobacco product administration carries with it challenges unseen in traditional studies of pharmaceutical products. ClinQuick®, Celerion’s proprietary clinical electronic data acquisition system, includes a module specific to tobacco-related studies to ensure accurate timing of product administration and accountability.
Our extensive experience with both the pharmaceutical and tobacco industries, coupled with our commitment to GCP and ICH principles, ensures that Celerion will serve as a capable partner to evaluate reduced exposure and reduced harm products.